The CCR2 receptor as a therapeutic target

Bibliography

• GINSBERG MH, DÍAZ-GONZÁLEZ F: Cell adhesion molecules and endothelial cells in arthritis. In: Arthritis and allied conditions. A textbook of Rheumatology. Koopman WJ (Ed.) Williams and Wilkins, Baltimore MA (1997):479-489.
   Google Scholar
• ROT A, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann. Rev. Immunol. (2004) 22:891-928.
   Google Scholar
• BAGGIOLINI M: Chemokines and leukocyte traffic. Nature (1998) 392(6676):565-568.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, MACKAY CR, LANZAVECCHIA A: The role of chemokine receptors in primary, effector, and memory immune responses. Ann. Rev. Immunol. (2000) 18:593-620.
   Google Scholar
• THELEN M: Dancing to the tune of chemokines. Nat. Immunol. (2001) 2(2):129-134.
   PubMed Web of Science ®Google Scholar
• GARCIA-VICUNA R, GOMEZ-GAVIRO MV, DOMINGUEZ-LUIS MJ et al.: CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. (2004) 50(12):3866-3877.
   PubMed Web of Science ®Google Scholar
• MURPHY PM: International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. (2002) 54(2):227-229.
   PubMed Web of Science ®Google Scholar
• MANTOVANI A: The chemokine system: redundancy for robust outputs. Immunol. Today (1999) 20(6):254-257.
   PubMedGoogle Scholar
• PROUDFOOT AE, POWER CA, ROMMEL C, WELLS TN: Strategies for chemokine antagonists as therapeutics. Semin. Immunol. (2003) 15(1):57-65.
   PubMed Web of Science ®Google Scholar
• DAWSON TC, KUZIEL WA, OSAHAR TA, MAEDA N: Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (1999) 143(1):205-211.
   PubMed Web of Science ®Google Scholar
• ANDRES PG, BECK PL, MIZOGUCHI E et al.: Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J. Immunol. (2000) 164(12):6303-6312.
   PubMed Web of Science ®Google Scholar
• FIFE BT, HUFFNAGLE GB, KUZIEL WA, KARPUS WJ: CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med. (2000) 192(6):899-905.
   PubMed Web of Science ®Google Scholar
• ABBADIE C, LINDIA JA, CUMISKEY AM et al.: Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. USA (2003) 100(13):7947-7952.
   PubMed Web of Science ®Google Scholar
• MAUS UA, WAELSCH K, KUZIEL WA et al.: Monocytes are potent facilitators of alveolar neutrophil emigration during lung inflammation: role of the CCL2-CCR2 axis. J. Immunol. (2003) 170(6):3273-3278.
   PubMed Web of Science ®Google Scholar
• GAUPP S, PITT D, KUZIEL WA, CANNELLA B, RAINE CS: Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am. J. Pathol. (2003) 162(1):139-150.
   PubMed Web of Science ®Google Scholar
• MOORE BB, PETERS-GOLDEN M, CHRISTENSEN PJ et al.: Alveolar epithelial cell inhibition of fibroblast proliferation is regulated by MCP-1/CCR2 and mediated by PGE2. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 284(2):L342-L349.
   PubMed Web of Science ®Google Scholar
• KUANG Y, WU Y, JIANG H, WU D: Selective G protein coupling by CC chemokine receptors. J. Biol. Chem. (1996) 271(8):3975-3978.
   PubMed Web of Science ®Google Scholar
• OGILVIE P, PAOLETTI S, CLARK-LEWIS I, UGUCCIONI M: Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood (2003) 102(3):789-794.
   PubMed Web of Science ®Google Scholar
• OGILVIE P, BARDI G, CLARK-LEWIS I, BAGGIOLINI M, UGUCCIONI M: Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood (2001) 97(7):1920-1924.
   PubMed Web of Science ®Google Scholar
• KOCH AE, KUNKEL SL, HARLOW LA et al.: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. (1992) 90(3):772-779.
   PubMed Web of Science ®Google Scholar
• HOSAKA S, AKAHOSHI T, WADA C, KONDO H: Expression of the chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol. (1994) 97(3):451-457.
   PubMed Web of Science ®Google Scholar
• CONNOR SJ, PARASKEVOPOULOS N, NEWMAN R et al.: CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn’s disease. Gut (2004) 53(9):1287-1294.
   PubMed Web of Science ®Google Scholar
• WEBER KS, NELSON PJ, GRONE HJ, WEBER C: Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium. Arterioscler. Thromb. Vasc. Biol. (1999) 19(9):2085-2093.
   PubMed Web of Science ®Google Scholar
• CONNOR RI, SHERIDAN KE, CERADINI D, CHOE S, LANDAU NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. (1997) 185(4):621-628.
   PubMed Web of Science ®Google Scholar
• SMITH JB, HAYNES MK: Rheumatoid arthritis – a molecular understanding. Ann. Intern. Med. (2002) 136(12):908-922.
   PubMed Web of Science ®Google Scholar
• SZEKANECZ Z, KIM J, KOCH AE: Chemokines and chemokine receptors in rheumatoid arthritis. Semin. Immunol. (2003) 15(1):15-21.
   PubMed Web of Science ®Google Scholar
• NANKI T, NAGASAKA K, HAYASHIDA K, SAITA Y, MIYASAKA N: Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J. Immunol. (2001) 167(9):5381-5385.
   PubMed Web of Science ®Google Scholar
• KATSCHKE KJ JR, ROTTMAN JB, RUTH JH et al.: Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum. (2001) 44(5):1022-1032.
   PubMed Web of Science ®Google Scholar
• PATEL DD, ZACHARIAH JP, WHICHARD LP: CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin. Immunol. (2001) 98(1):39-45.
   PubMed Web of Science ®Google Scholar
• AKAHOSHI T, WADA C, ENDO H et al.: Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. Arthritis Rheum. (1993) 36(6):762-771.
   PubMed Web of Science ®Google Scholar
• OGATA H, TAKEYA M, YOSHIMURA T, TAKAGI K, TAKAHASHI K: The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. (1997) 182(1):106-114.
   PubMed Web of Science ®Google Scholar
• GONG JH, CLARK-LEWIS I: Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J. Exp. Med. (1995) 181(2):631-640.
   PubMed Web of Science ®Google Scholar
• GONG JH, RATKAY LG, WATERFIELD JD, CLARK-LEWIS I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. (1997) 186(1):131-137.
   PubMed Web of Science ®Google Scholar
• GONG JH, YAN R, WATERFIELD JD, CLARK-LEWIS I: Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology (2004) 43(1):39-42.
   PubMed Web of Science ®Google Scholar
• GUGLIELMOTTI A, D’ONOFRIO E, COLETTA I et al.: Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-α production. Inflamm. Res. (2002) 51(5):252-258.
   PubMed Web of Science ®Google Scholar
• QUINONES MP, AHUJA SK, JIMENEZ F et al.: Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. (2004) 113(6):856-866.
   PubMed Web of Science ®Google Scholar
• BRUHL H, CIHAK J, SCHNEIDER MA et al.: Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol. (2004) 172(2):890-898.
   PubMed Web of Science ®Google Scholar
• QUINONES MP, ESTRADA CA, KALKONDE Y et al.: The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J. Mol. Med. (2005) 83(9):672-681.
   PubMed Web of Science ®Google Scholar
• HARINGMAN J, GERLAG D, SMEETS J et al.: A randomized placebo controlled trial with anti-MCP-1 (CCL2) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. (2004) 50(9):S238.
   Google Scholar
• FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38(6):727-735.
   PubMed Web of Science ®Google Scholar
• HICKEY WF: The pathology of multiple sclerosis: a historical perspective. J. Neuroimmunol. (1999) 98(1):37-44.
   PubMed Web of Science ®Google Scholar
• KENNEDY KJ, STRIETER RM, KUNKEL SL, LUKACS NW, KARPUS WJ: Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1. J. Neuroimmunol. (1998) 92(1-2):98-108.
   PubMed Web of Science ®Google Scholar
• GLABINSKI AR, TANI M, TUOHY VK, TUTHILL RJ, RANSOHOFF RM: Central nervous system chemokine mRNA accumulation follows initial leukocyte entry at the onset of acute murine experimental autoimmune encephalomyelitis. Brain Behav. Immun. (1995) 9(4):315-330.
   PubMed Web of Science ®Google Scholar
• BRODMERKEL CM, HUBER R, COVINGTON M et al.: Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INC.B3344. J. Immunol. (2005) 175(8):5370-5378.
   PubMed Web of Science ®Google Scholar
• IZIKSON L, KLEIN RS, CHARO IF, WEINER HL, LUSTER AD: Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. (2000) 192(7):1075-1080.
   PubMed Web of Science ®Google Scholar
• HUANG DR, WANG J, KIVISAKK P, ROLLINS BJ, RANSOHOFF RM: Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell Type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. (2001) 193(6):713-726.
   PubMed Web of Science ®Google Scholar
• SORENSEN TL, SELLEBJERG F, JENSEN CV, STRIETER RM, RANSOHOFF RM: Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis. Eur. J. Neurol. (2001) 8(6):665-672.
   PubMed Web of Science ®Google Scholar
• SORENSEN TL, RANSOHOFF RM, STRIETER RM, SELLEBJERG F: Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur. J. Neurol. (2004) 11(7):445-449.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420(6917):868-874.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, LIBBY P, SCHONBECK U, YAN ZQ: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. (2002) 91(4):281-291.
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis – an inflammatory disease. N. Engl. J. Med. (1999) 340(2):115-126.
   PubMed Web of Science ®Google Scholar
• MACH F: The role of chemokines in atherosclerosis. Curr. Atheroscler. Rep. (2001) 3(3):243-251.
   PubMedGoogle Scholar
• NELKEN NA, COUGHLIN SR, GORDON D, WILCOX JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. (1991) 88(4):1121-1127.
   PubMed Web of Science ®Google Scholar
• YU X, DLUZ S, GRAVES DT et al.: Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc. Natl. Acad. Sci. USA (1992) 89(15):6953-6957.
   PubMed Web of Science ®Google Scholar
• AIELLO RJ, BOURASSA PA, LINDSEY S et al.: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (1999) 19(6):1518-1525.
   PubMed Web of Science ®Google Scholar
• GOSLING J, SLAYMAKER S, GU L et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. (1999) 103(6):773-778.
   PubMed Web of Science ®Google Scholar
• GU L, OKADA Y, CLINTON SK et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell (1998) 2(2):275-281.
   PubMed Web of Science ®Google Scholar
• BORING L, GOSLING J, CLEARY M, CHARO IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 394(6696):894-897.
   PubMed Web of Science ®Google Scholar
• VEILLARD NR, KWAK B, PELLI G et al.: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. (2004) 94(2):253-261.
   PubMed Web of Science ®Google Scholar
• VEILLARD NR, STEFFENS S, PELLI G et al.: Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 112(6):870-878.
   PubMed Web of Science ®Google Scholar
• VALDES AM, WOLFE ML, O’BRIEN EJ et al.: Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler. Thromb. Vasc. Biol. (2002) 22(11):1924-1928.
   PubMed Web of Science ®Google Scholar
• GONZALEZ P, ALVAREZ R, BATALLA A et al.: Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. (2001) 2(4):191-195.
   PubMed Web of Science ®Google Scholar
• SZALAI C, DUBA J, PROHASZKA Z et al.: Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis (2001) 158(1):233-239.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. (1997) 336(14):973-979.
   PubMed Web of Science ®Google Scholar
• MORENO PR, BERNARDI VH, LOPEZ-CUELLAR J et al.: Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation (1996) 94(12):3098-3102.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, OTT I, GAWAZ M, PUCHNER G, SCHOMIG A: Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J. Am. Coll. Cardiol. (1996) 27(4):819-824.
   PubMed Web of Science ®Google Scholar
• YASUKAWA H, IMAIZUMI T, MATSUOKA H, NAKASHIMA A, MORIMATSU M: Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation (1997) 95(6):1515-1522.
   PubMed Web of Science ®Google Scholar
• SIMON DI, DHEN Z, SEIFERT P et al.: Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation in vascular repair after angioplasty. J. Clin. Invest. (2000) 105(3):293-300.
   PubMed Web of Science ®Google Scholar
• FURUKAWA Y, MATSUMORI A, OHASHI N et al.: Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res (1999) 84(3):306-314.
   PubMed Web of Science ®Google Scholar
• NI W, EGASHIRA K, KITAMOTO S et al.: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation (2001) 103(16):2096-2101.
   PubMed Web of Science ®Google Scholar
• HORVATH C, WELT FG, NEDELMAN M, RAO P, ROGERS C: Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. (2002) 90(4):488-494.
   PubMed Web of Science ®Google Scholar
• CIPOLLONE F, MARINI M, FAZIA M et al.: Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. (2001) 21(3):327-334.
   PubMed Web of Science ®Google Scholar
• COCCHI F, DEVICO AL, GARZINO-DEMO A et al.: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 270(5243):1811-1815.
   PubMed Web of Science ®Google Scholar
• ALKHATIB G, COMBADIERE C, BRODER CC et al.: CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272(5270):1955-1958.
   PubMed Web of Science ®Google Scholar
• DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381(6584):661-666.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, RUCKER J, YI Y et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 85(7):1149-1158.
   PubMed Web of Science ®Google Scholar
• BERGER EA, DOMS RW, FENYO EM et al.: A new classification for HIV-1. Nature (1998) 391(6664):240.
   PubMed Web of Science ®Google Scholar
• RUCKER J, EDINGER AL, SHARRON M et al.: Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. (1997) 71(12):8999-9007.
   PubMed Web of Science ®Google Scholar
• SOZZANI S, INTRONA M, BERNASCONI S et al.: MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. J. Leukoc. Biol. (1997) 62(1):30-33.
   PubMed Web of Science ®Google Scholar
• VICENZI E, ALFANO M, GHEZZI S et al.: Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1α, and MCP-3, and enhancement by MCP-1. J. Leukoc. Biol. (2000) 68(3):405-412.
   PubMed Web of Science ®Google Scholar
• FANTUZZI L, SPADARO F, VALLANTI G et al.: Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood (2003) 102(7):2334-2337.
   PubMed Web of Science ®Google Scholar
• SMITH MW, DEAN M, CARRINGTON M et al.: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science (1997) 277(5328):959-965.
   PubMed Web of Science ®Google Scholar
• KOSTRIKIS LG, HUANG Y, MOORE JP et al.: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. (1998) 4(3):350-353.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-FRADE JM, DEL REAL G, SERRANO A et al.: Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J. (2004) 23(1):66-76.
   PubMed Web of Science ®Google Scholar
• MILLER M, ZHAN M, HAVAS S: High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. (2005) 165(18):2063-2068.
   PubMedGoogle Scholar
• KIPSHIDZE NN, TSAPENKO MV, LEON MB, STONE GW, MOSES JW: Update on drug-eluting coronary stents. Expert Rev. Cardiovasc. Ther. (2005) 3(5):953-968.
   PubMedGoogle Scholar